Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.80
MACK's Cash to Debt is ranked higher than
59% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. MACK: 0.80 )
MACK' s 10-Year Cash to Debt Range
Min: 0.8   Max: No Debt
Current: 0.8

Equity to Asset -0.59
MACK's Equity to Asset is ranked lower than
51% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. MACK: -0.59 )
MACK' s 10-Year Equity to Asset Range
Min: -4.85   Max: 0.24
Current: -0.59

-4.85
0.24
F-Score: 2
Z-Score: -5.83
M-Score: -3.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -182.94
MACK's Operating margin (%) is ranked higher than
65% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. MACK: -182.94 )
MACK' s 10-Year Operating margin (%) Range
Min: -2220.11   Max: -189.58
Current: -182.94

-2220.11
-189.58
Net-margin (%) -213.20
MACK's Net-margin (%) is ranked higher than
64% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. MACK: -213.20 )
MACK' s 10-Year Net-margin (%) Range
Min: -2284.59   Max: -186.58
Current: -213.2

-2284.59
-186.58
ROA (%) -72.29
MACK's ROA (%) is ranked higher than
57% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. MACK: -72.29 )
MACK' s 10-Year ROA (%) Range
Min: -110.9   Max: -71.71
Current: -72.29

-110.9
-71.71
ROC (Joel Greenblatt) (%) -839.55
MACK's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. MACK: -839.55 )
MACK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1483.52   Max: -1183.68
Current: -839.55

-1483.52
-1183.68
» MACK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

MACK Guru Trades in Q3 2012

Steven Cohen 866,000 sh (New)
» More
Q4 2012

MACK Guru Trades in Q4 2012

Steven Cohen Sold Out
» More
Q1 2014

MACK Guru Trades in Q1 2014

Murray Stahl 12,000 sh (New)
» More
Q2 2014

MACK Guru Trades in Q2 2014

Jim Simons 569,413 sh (New)
Paul Tudor Jones 13,622 sh (New)
Murray Stahl 12,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MACK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 17.04
MACK's P/S is ranked higher than
67% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. MACK: 17.04 )
MACK' s 10-Year P/S Range
Min: 1.79   Max: 17.03
Current: 17.04

1.79
17.03
EV-to-EBIT -8.86
MACK's EV-to-EBIT is ranked higher than
66% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MACK: -8.86 )
MACK' s 10-Year EV-to-EBIT Range
Min: -10.3   Max: -0.5
Current: -8.86

-10.3
-0.5
Current Ratio 1.14
MACK's Current Ratio is ranked higher than
54% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. MACK: 1.14 )
MACK' s 10-Year Current Ratio Range
Min: 1.14   Max: 4.51
Current: 1.14

1.14
4.51
Quick Ratio 1.14
MACK's Quick Ratio is ranked higher than
57% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. MACK: 1.14 )
MACK' s 10-Year Quick Ratio Range
Min: 1.14   Max: 4.51
Current: 1.14

1.14
4.51

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.15
MACK's Price/Median PS Value is ranked higher than
72% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. MACK: 2.15 )
MACK' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 1.68
Current: 2.15

0.23
1.68
Earnings Yield (Greenblatt) -11.30
MACK's Earnings Yield (Greenblatt) is ranked lower than
187% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. MACK: -11.30 )
MACK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -11.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MP6.Germany
Merrimack Pharmaceuticals Inc is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
» More Articles for MACK

Headlines

Articles On GuruFocus.com
No related article found.


More From Other Websites
Nasdaq stocks posting largest percentage increases Oct 24 2014
Fate Therapeutics (FATE) Crumbles: Stock Tumbles by 10.6% Oct 24 2014
Merrimack Pharmaceuticals (MACK) Looks Strong: Stock Up 8.6% Oct 24 2014
Illumina (ILMN) Looks Strong: Stock Gains 9.2% Oct 22 2014
NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% Oct 21 2014
Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% Oct 20 2014
Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 15.7% Oct 17 2014
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% Oct 16 2014
Synageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% Oct 16 2014
MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% Oct 15 2014
Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% Oct 13 2014
Why Merrimack (MACK) Could Be Positioned for a Surge? Oct 10 2014
Top 5 Biotech Stocks Over The Past Year Oct 06 2014
Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the... Sep 30 2014
How Merrimack Pharmaceuticals (MACK) Stock Stands Out in a Strong Industry Sep 29 2014
3 Biotech Stocks Under $10 to Trade for Breakouts Sep 26 2014
Will Merrimack (MACK) Continue to Surge Higher? Sep 26 2014
Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session Sep 26 2014
PharmaEngine and Merrimack Amend MM-398 License Agreement Sep 26 2014
Baxter and Merrimack Collaborate on Drug Development Sep 25 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK